ReviewFrontiers in immunology2022
IgA vasculitis update: Epidemiology, pathogenesis, and biomarkers.
Review in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 96 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
96 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- S100 proteins in IgA vasculitis and other systemic vasculitides - from pathogenic mechanisms to clinical biomarkers: a systematic review.Frontiers in immunology · 2026Pooled it
- Guidelines for the diagnosis and management of childhood immunoglobulin A vasculitis.World journal of pediatrics : WJP · 2025Guideline
- Efficacy and safety of tacrolimus in the treatment of Henoch-Schönlein purpura nephritis: systematic review and meta-analysis.BMC nephrology · 2025Pooled it
- National recommendations for the management of children and young people with IgA vasculitis: a best available evidence, group agreement-based approach.Archives of disease in childhood · 2024Guideline
- Diagnostic and prognostic value of galactose-deficient IgA1 in patients with IgA nephropathy: an updated systematic review with meta-analysis.Frontiers in immunology · 2023Pooled it
- Abdominal pain in pediatric immunoglobulin A vasculitis: Risk factors and severity predictors in a multicenter cohort.Journal of pediatric gastroenterology and nutrition · 2026Article
- Profiling immune cell subsets in pediatric IgA vasculitis and immune thrombocytopenia: insights into disease pathogenesis and clinical correlates.Pediatric research · 2026Article
- A case of severe strongyloidiasis complicating immunosuppressive therapy initiated for IgA vasculitis.Parasites, hosts and diseases · 2026Article
- Nasal Manifestations of Immunoglobulin A (IgA) Vasculitis in an Adolescent Patient: A Case Report.Cureus · 2026Article
- New epidemiological characteristics of childhood IgA vasculitis in the post-COVID-19 era: a single-center retrospective cohort study.Pediatric rheumatology online journal · 2026Article
- Immunoglobulin A (IgA)-Mediated Vasculitis as a Paraneoplastic Clue in Chronic Lymphocytic Leukemia: A Case Report.Cureus · 2026Article
- Article
- The ratio of TG/CysC is a significant indicator of nephritis in children with IgA vasculitis.Journal of clinical biochemistry and nutrition · 2026Article
- Serum SCUBE1 and SCUBE2 Levels in Children with Immunoglobulin A Vasculitis: An Exploratory Study.Rheumatology and therapy · 2026Article
- Article
- Impact of MEFV mutations on inflammatory activity and long-term relapse in pediatric IgA vasculitis.BMC pediatrics · 2026Article
- Demographic, Clinical, and Laboratory Characteristics of Pediatric IgA Vasculitis: A Retrospective Five-Year Single-Center Experience.Journal of clinical medicine · 2026Article
- Short-chain fatty acids (SCFAs) and the "Regulatory" B-cell: why fiber diet may reduce relapse in IgA vasculitis.Annals of medicine and surgery (2012) · 2026Article
- Complement-Mediated Kidney Diseases: Role of Alternative Pathway in Glomerular Inflammation.Kidney international reports · 2026Review
- Atypical Vasculitis Phenotype with Concomitant Medium- and Small-Vessel Involvement: A Case Report Highlighting Diagnostic and Pathological Challenges.International journal of nephrology and renovascular disease · 2026Article
36 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunoglobulin A vasculitis (IgAV), formerly known as Henoch-Schönlein purpura, is the most common systemic vasculitis in children, characterized by diverse clinical manifestations with a wide spectrum ranging from isolated cutaneous vasculitis to systemic involvement. The incidence of IgAV is geographically and ethnically variable, with a prevalence in autumn and winter, suggesting a driving role that genetic and environmental factors play in the disease. Although IgAV has a certain degree of natural remission, it varies widely among individuals. Some patients can suffer from severe renal involvement and even progress to end-stage renal disease. Its pathogenesis is complex and has not been fully elucidated. The formation of galactose-deficient IgA1 (Gd-IgA1) and related immune complexes plays a vital role in promoting the occurrence and development of IgAV nephritis. In addition, neutrophil activation is stimulated through the binding of IgA to the Fc alpha receptor I expressed on its surface, resulting in systemic vascular inflammation and tissue damage. Starting from the epidemiological characteristics, this article will review the role of immunological factors such as Gd-IgA1, autoantibodies, circulating immune complexes, complement system, cellular immunization, and the contributions of environmental and genetic factors in the pathogenesis of IgAV, and conclude with the major biomarkers for IgAV.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.